These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12810646)

  • 1. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
    Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
    Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
    Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
    Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
    Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
    Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
    Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
    Doloff JC; Waxman DJ; Jounaidi Y
    Hum Gene Ther; 2008 Dec; 19(12):1383-400. PubMed ID: 18771358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].
    Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE; Merron A; Vassaux G; Keith WN
    Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
    Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
    Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus.
    Qi Y; Guo H; Hu N; He D; Zhang S; Chu Y; Huang Y; Li X; Sun L; Jin N
    Toxicol Appl Pharmacol; 2014 Oct; 280(2):362-9. PubMed ID: 25151223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.
    Su CQ; Sham J; Xue HB; Wang XH; Chua D; Cui ZF; Peng LH; Li LF; Jiang LH; Wu MC; Qian QJ
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):591-603. PubMed ID: 15243805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.